U.S. healthcare supply chain giant Cardinal Health has announced it will acquire a majority stake in Solaris Health, a leading urology-focused medical network, for approximately \$2.4 billion. The deal marks an important step in Cardinal’s expansion beyond traditional distribution into specialized clinical services.
Solaris Health is one of the largest urology specialty groups in the United States, operating across 14 states with more than 750 medical facilities and over 700 specialist physicians. Its services span urologic disease management, men’s health, and oncology-related treatments. With the rising incidence of conditions such as prostate cancer, bladder cancer, and benign prostatic hyperplasia, the urology sector is seen as a field with steady and long-term medical demand.
Under the agreement, Cardinal Health will hold about 75% ownership of Solaris Health, while existing physician shareholders and management will retain the remaining stake. After the transaction, Solaris Health will continue to operate under its own brand but will gain access to Cardinal’s resources in supply chain management, pharmaceutical distribution, digital systems, and clinical research.
Cardinal Health stated that the acquisition will not only expand its influence in the U.S. urology market but also accelerate its transformation from a pure distributor of drugs and devices to an integrated healthcare services provider that combines supply chain + clinical services + specialty networks. Despite revenue falling short of expectations this quarter, the company raised its full-year earnings forecast, underscoring confidence in the deal’s prospects.
Analysts noted that this acquisition reflects a broader trend in the U.S. healthcare sector: large supply chain companies are moving aggressively into specialty care, using mergers and acquisitions to strengthen physician networks and patient engagement in response to evolving payment models and competitive pressures. At the same time, the consolidation of specialty services could improve treatment efficiency and medication adherence.
However, some observers warned that the influx of large-scale capital into specialty care could marginalize smaller practices and lead to concerns about access to care as services become more concentrated. Regulators are expected to closely monitor the impact of such consolidations on competition and patient rights.
This acquisition represents a strategic milestone for Cardinal Health and highlights the shifting dynamics of the U.S. healthcare industry. Balancing capital-driven growth with patient-centered care will remain a central challenge moving forward.
